Why Healthcare Investing Demands a Second Regulatory Lens
A Category II AIF investing in a healthcare or pharmaceutical company faces standard AIF compliance obligations exactly like any other fund — but the investee company itself operates under a dense, sector-specific regulatory regime that directly shapes investment risk. A fund's diligence and monitoring discipline needs to genuinely engage with this second regulatory layer, not treat it as background noise a portfolio company's own legal team handles independently.
The Drugs and Cosmetics Act, 1940: The Foundational Framework
Any investee company manufacturing, selling, or distributing pharmaceuticals or certain cosmetics operates under the Drugs and Cosmetics Act, 1940 and its associated rules — covering manufacturing licences, quality standards, and marketing approval requirements. For an AIF's diligence, this means verifying the investee holds current, valid manufacturing/marketing licences for its actual product portfolio, understanding whether any products are under regulatory scrutiny or facing licence renewal risk, and recognising that a licence suspension or cancellation can be a genuinely existential event for a pharma investee in a way that doesn't have a clean analogue in most other sectors.
Clinical Trial Regulation: A Distinct Diligence Layer for Drug Development Companies
Where an investee company is engaged in drug development (rather than purely generic manufacturing or distribution), clinical trial conduct falls under India's specific clinical trial regulatory framework, requiring Central Drugs Standard Control Organisation (CDSCO) approval for trials, adherence to Good Clinical Practice standards, and specific informed-consent and ethics-committee oversight requirements. For a fund investing in a clinical-stage company, understanding exactly which trial phase the company's lead assets are in, and the realistic regulatory timeline and risk to reach approval, is often the single most important diligence question — arguably more important than near-term financial metrics for an early clinical-stage investee.
FDI Policy: The Brownfield vs Greenfield Distinction
Foreign investment into Indian pharmaceutical companies is subject to a specific distinction in India's FDI policy between greenfield and brownfield pharma investment:
- Greenfield pharma investment (setting up new manufacturing/business from scratch) is generally permitted up to 100% under the automatic route
- Brownfield pharma investment (acquiring an existing pharmaceutical company/business) is subject to a lower automatic-route threshold, with investment beyond that threshold requiring government route approval, and specific conditions attached even within the automatic-route portion — designed to balance foreign capital access against domestic manufacturing capacity and essential medicine availability concerns This distinction matters directly for an AIF with foreign investors (or foreign co-investors) participating in a pharma-sector investment — the underlying transaction's brownfield/greenfield characterisation, and the specific current thresholds and conditions in force, need to be confirmed before assuming a straightforward automatic-route foreign investment is available.
Medical Devices: A Related but Distinct Regulatory Track
Medical device companies operate under India's Medical Device Rules — a related but structurally distinct regulatory framework from pharmaceutical drug regulation, with its own classification system (Class A through D, based on risk level) and corresponding registration/licensing requirements. A fund investing across both pharma and medical device portfolio companies needs to recognise these aren't simply the same regulatory framework applied to a different product type — the specific compliance requirements diverge meaningfully.
Valuation Challenges: IP-Heavy, Milestone-Driven Businesses
Healthcare and pharma investments — particularly in drug development or novel medical technology — often involve valuing a business whose primary asset is intellectual property and regulatory approval progress, rather than current revenue or cash flow. This pushes valuation methodology toward milestone-based and probability-weighted approaches (assigning value based on the probability-adjusted likelihood of reaching specific development/regulatory milestones) rather than the comparable-company or DCF approaches that dominate most other sector valuations (see our Valuation of Unlisted Securities article for the broader AIF valuation framework this fits within).
Why Healthcare Investing Rewards Genuine Sector Specialisation
Given the density of sector-specific regulation — manufacturing licensing, clinical trial oversight, FDI's brownfield/greenfield distinction, medical device classification — healthcare and pharma-focused AIFs benefit disproportionately from fund managers and advisory teams with genuine healthcare-sector regulatory fluency, not just general private equity diligence capability applied to a healthcare target.
Supporting Healthcare-Focused Fund Diligence
We advise healthcare and pharma-focused fund managers on structuring investments with appropriate sector-specific regulatory diligence, and coordinate with specialist healthcare regulatory counsel where an investment's complexity warrants it.
This article is for general informational purposes and does not constitute investment, regulatory, or legal advice specific to any healthcare or pharma sector investment.